Literature DB >> 29580100

Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell-Derived RPE and Photoreceptor Cells.

Anai Gonzalez-Cordero1, Debbie Goh1, Kamil Kruczek1, Arifa Naeem1, Milan Fernando1, Sophia-Martha Kleine Holthaus1,2, Matsuki Takaaki1, Samuel J I Blackford1, Magdalena Kloc1, Leticia Agundez1, Robert D Sampson1, Shyamanga Borooah3, Patrick Ovando-Roche1, Manjit S Mehat1, Emma L West1, Alexander J Smith1, Rachael A Pearson1, Robin R Ali1.   

Abstract

Adeno-associated viral vectors are showing great promise as gene therapy vectors for a wide range of retinal disorders. To date, evaluation of therapeutic approaches has depended almost exclusively on the use of animal models. With recent advances in human stem cell technology, stem cell-derived retina now offers the possibility to assess efficacy in human organoids in vitro. Here we test six adeno-associated virus (AAV) serotypes [AAV2/2, AAV2/9, AAV2/8, AAV2/8T(Y733F), AAV2/5, and ShH10] to determine their efficiency in transducing mouse and human pluripotent stem cell-derived retinal pigment epithelium (RPE) and photoreceptor cells in vitro. All the serotypes tested were capable of transducing RPE and photoreceptor cells in vitro. AAV ShH10 and AAV2/5 are the most efficient vectors at transducing both mouse and human RPE, while AAV2/8 and ShH10 achieved similarly robust transduction of human embryonic stem cell-derived cone photoreceptors. Furthermore, we show that human embryonic stem cell-derived photoreceptors can be used to establish promoter specificity in human cells in vitro. The results of this study will aid capsid selection and vector design for preclinical evaluation of gene therapy approaches, such as gene editing, that require the use of human cells and tissues.

Entities:  

Keywords:  AAV serotypes; gene therapy; pluripotent stem cells; retinal organoids

Mesh:

Year:  2018        PMID: 29580100     DOI: 10.1089/hum.2018.027

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  22 in total

Review 1.  Biomaterial substrate modifications that influence cell-material interactions to prime cellular responses to nonviral gene delivery.

Authors:  Amy Mantz; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-08

2.  Reproducibility and staging of 3D human retinal organoids across multiple pluripotent stem cell lines.

Authors:  Elizabeth E Capowski; Kayvan Samimi; Steven J Mayerl; M Joseph Phillips; Isabel Pinilla; Sara E Howden; Jishnu Saha; Alex D Jansen; Kimberly L Edwards; Lindsey D Jager; Katherine Barlow; Rasa Valiauga; Zachary Erlichman; Anna Hagstrom; Divya Sinha; Valentin M Sluch; Xitiz Chamling; Donald J Zack; Melissa C Skala; David M Gamm
Journal:  Development       Date:  2019-01-09       Impact factor: 6.868

Review 3.  Organs to Cells and Cells to Organoids: The Evolution of in vitro Central Nervous System Modelling.

Authors:  Dario Pacitti; Riccardo Privolizzi; Bridget E Bax
Journal:  Front Cell Neurosci       Date:  2019-04-09       Impact factor: 5.505

4.  Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9.

Authors:  Jiahui Wu; Oliver H Bell; David A Copland; Alison Young; John R Pooley; Ryea Maswood; Rachel S Evans; Peng Tee Khaw; Robin R Ali; Andrew D Dick; Colin J Chu
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

5.  AAV-Mediated Gene Delivery to 3D Retinal Organoids Derived from Human Induced Pluripotent Stem Cells.

Authors:  Marcela Garita-Hernandez; Fiona Routet; Laure Guibbal; Hanen Khabou; Lyes Toualbi; Luisa Riancho; Sacha Reichman; Jens Duebel; Jose-Alain Sahel; Olivier Goureau; Deniz Dalkara
Journal:  Int J Mol Sci       Date:  2020-02-03       Impact factor: 5.923

Review 6.  Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances.

Authors:  Michelle E McClements; Federica Staurenghi; Robert E MacLaren; Jasmina Cehajic-Kapetanovic
Journal:  Front Neurosci       Date:  2020-11-11       Impact factor: 4.677

7.  Gene Therapy of Dominant CRX-Leber Congenital Amaurosis using Patient Stem Cell-Derived Retinal Organoids.

Authors:  Kamil Kruczek; Zepeng Qu; James Gentry; Benjamin R Fadl; Linn Gieser; Suja Hiriyanna; Zachary Batz; Mugdha Samant; Ananya Samanta; Colin J Chu; Laura Campello; Brian P Brooks; Zhijian Wu; Anand Swaroop
Journal:  Stem Cell Reports       Date:  2021-01-28       Impact factor: 7.765

Review 8.  Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.

Authors:  Thilo M Buck; Jan Wijnholds
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

9.  Modeling and Rescue of RP2 Retinitis Pigmentosa Using iPSC-Derived Retinal Organoids.

Authors:  Amelia Lane; Katarina Jovanovic; Ciara Shortall; Daniele Ottaviani; Anna Brugulat Panes; Nele Schwarz; Rosellina Guarascio; Matthew J Hayes; Arpad Palfi; Naomi Chadderton; G Jane Farrar; Alison J Hardcastle; Michael E Cheetham
Journal:  Stem Cell Reports       Date:  2020-06-11       Impact factor: 7.765

Review 10.  Pluripotent stem cell-derived retinal organoids for disease modeling and development of therapies.

Authors:  Kamil Kruczek; Anand Swaroop
Journal:  Stem Cells       Date:  2020-06-07       Impact factor: 5.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.